Clinical trials: Diabetic Nephropathies
Diabetic Nephropathy
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
This Phase 2A study is an adaptive design pilot study investigating the efficacy and safety of daily Acthar administration in diabetic patients with nephropathy and proteinuria.
- Trial name
- NCT01601236
- Testing
- Repository Corticotropin Injection
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mallinckrodt
Diabetic Kidney Disease
A Phase 2b Diabetic Kidney Disease Study
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
- Trial name
- NCT04170543
- Testing
- MEDI3506, Dapagliflozin
- Where
- 97 sites in United States, Argentina and 5 more
- Volunteers
- 609 people
- Sponsor
- AstraZeneca
Diabetic Nephropathies, Coronary Artery Disease
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Despite improvements during the past 20 years in blood glucose and blood pressure control, diabetic kidney disease remains one of the most important causes of health problems in patients with diabetes.
- Trial name
- NCT02017171
- Testing
- Allopurinol
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 530 people
- Sponsor
- Alessandro Doria
Diabetic Kidney Disease
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
- Trial name
- MOSAIC (NCT04026165)
- Testing
- SEL
- Where
- 111 sites in United States, Australia and 3 more
- Volunteers
- 384 people
- Sponsor
- Gilead Sciences
Chronic Kidney Disease
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function.
- Trial name
- NCT04736628
- Testing
- Avenciguat
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
Diabetic Nephropathy
Renoprotection in Early Diabetic Nephropathy in Pima Indians
This investigation is a randomized, double-blinded, placebo-controlled clinical trial in adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine ration less than 30 mg/g) or microalbuminuria…
- Trial name
- NCT00340678
- Testing
- Losartan
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage…
- Trial name
- CREDENCE (NCT02065791)
- Testing
- Canagliflozin
- Where
- 575 sites in United States, Argentina and 32 more
- Volunteers
- 4,401 people
- Sponsor
- Janssen Research & Development, LLC
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Diabetes
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress…
- Trial name
- NCT01350388
- Testing
- Febuxostat
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor.
- Trial name
- NCT02010242
- Testing
- GKT137831
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 136 people
- Sponsor
- Calliditas Therapeutics AB
Diabetes Mellitus, Type 1, Nephropathy
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Over 1.25 million Americans have type 1 diabetes (T1D), increasing risk for early death from cardiorenal disease. The strongest risk factor for cardiovascular disease (CVD) and mortality in T1D is diabetic kidney disease (DKD).
- Conditions
- Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes
- Trial name
- CASPER (NCT03618420)
- Testing
- Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Chronic Kidney Disease
Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function
The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.
- Trial name
- NCT00586261
- Testing
- Pioglitazone, Nitroglycerin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
ESRD, Diabetes
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients…
- Conditions
- ESRD, Diabetes, CAPD, APD
- Trial name
- Impendia (NCT00567489)
- Testing
- Physioneal, Dianeal, Extraneal
- Where
- 19 sites in Hong Kong, Russia and 3 more
- Volunteers
- 137 people
- Sponsor
- Vantive Health LLC
Non-diabetic Nephropathy
To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy
The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.
- Trial name
- ARIA (NCT01302899)
- Testing
- Aliskiren, Hydrochlorothiazide (HCTZ), Ramipril
- Where
- 2 sites in Netherlands
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
This study will assess the effect of anemia correction with NeoRecormon on cardiac structure and function in patients with early diabetic nephropathy.
- Trial name
- NCT00354341
- Testing
- Epoetin beta
- Where
- 63 sites in Austria, Brazil and 15 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche